N-Acetylcysteine Augmentation in Treatment of Refractory Obsessive-Compulsive Disorder

N-Acetylcysteine Augmentation in Treatment of Refractory Obsessive-Compulsive Disorder, a double blind randomized placebo controlled clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201103243930N4

Enrollment

Registered

2011-04-11

Start date

2011-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: N-Acetylcysteine (at a standard dose titrated up to 1200 mg within the first week) + SSRI. Intervention 2: Placebo + SSRI.

Treatment - Drugs

Placebo

N-Acetylcysteine (at a standard dose titrated up to 1200 mg within the first week) + SSRI

Placebo + SSRI

Eligibility

Sex/Gender

All

Age

10 Years to 20 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria are: DSM-IV diagnosis of OCD; symptoms of at least 1 year duration, moderate to severe OCD symptoms (Y-BOCS > 16), and failure of an adequate trial of an SSRI. Exclusion Criteria are: primary diagnosis of a psychotic disorder, active substance abuse or dependence, unstable medical condition, prior exposure to N-Acetylcysteine, pregnancy, breastfeeding, or intent to become pregnant during study, evidence of active liver disease, seizure disorder, and active suicidal ideation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Yale-Brown Obsessive-Compulsive Scale. Timepoint: every 2 weeks for 10 weeks. Method of measurement: Interview.	—

Secondary

Measure	Time frame
Clinical Global Impression. Timepoint: every 2 weeks for 10 weeks. Method of measurement: Self-report.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026